Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849651 · ClinicalTrials.gov registry record · Phase 2
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
A Phase 2 study of Hodgkin Lymphoma and Acute Myeloid Leukemia (AML), sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT03849651 is a Phase 2 study of Hodgkin Lymphoma and Acute Myeloid Leukemia (AML) that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 69 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03849651, a Phase 2 study of Hodgkin Lymphoma and Acute Myeloid Leukemia (AML), is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT). Patients with a suitable HLA matched sibling or unrelated donor identified will be eligible for participation ONLY if the donor is not available in the necessary time. The purpose of the study is to learn more about the effects (good and bad) of transplanting blood cells donated by a family member, and that have been modified in a laboratory to remove the type of T cells known to cause graft-vs.-host disease, to children and young adults with a high risk cancer that is in remission but is at high risk of relapse. This study will give donor cells that have been TCRαβ-depleted. The TCR (T-cell receptor) is a molecule that is found only on T cells. These T-cell receptors are made up of two proteins that are linked together. About 95% of all T-cells have a TCR that is composed of an alpha protein linked to a beta protein, and these will be removed. This leaves only the T cells that have a TCR made up of a gamma protein linked to a delta protein. This donor cell infusion will be followed by an additional infusion of donor memory cells (CD45RA-depleted) after donor cell engraftment. This study will be testing the safety and effects of the chemotherapy and the donor blood cell infusions on the transplant recipient's disease and overall survival.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Thiotepa
- BIOLOGICAL Fludarabine
- BIOLOGICAL G-csf
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2026-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03849651
The ClinicalTrials.gov registry entry for NCT03849651 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (58% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03849651 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03849651 about?
NCT03849651 is a clinical study titled "TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies". Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT). Patients with a suitable HLA matched sibling or unrelated donor identified will be eligible for participation ONLY if the donor is no...
What is the current status of trial NCT03849651?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2019-01-31. Estimated completion is 2026-06-07.
What conditions does trial NCT03849651 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Chronic Myeloid Leukemia (CML).
What interventions are being tested in trial NCT03849651?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Thiotepa (DRUG), Fludarabine (BIOLOGICAL), G-csf (BIOLOGICAL).
Who is sponsoring clinical trial NCT03849651?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849651 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.